Aryl hydrocarbon receptor is a prognostic biomarker and is correlated with immune responses in cervical cancer. Issue 2 (20th December 2021)

• Record Type: Journal Article
• Authors: Wang, Jiasui; Mijiti, Yilidana; Chen, Yalin; Liu, Zaoling
• Is Part Of: Bioengineered. Volume 12:Issue 2(2021)
• Page Start: 11922
• Page End: 11935
• Publication Date: 2021-12-20
• Subjects: AHR -- cervical cancer -- prognosis -- tumor-infiltrating -- bioinformatics; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.2006953
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Aryl hydrocarbon receptor (AHR) plays an important role in tumor development. However, its function in cervical cancer has not been fully elucidated. We evaluated the ten genes that are predicted to associate with AHR protein interaction. The comprehensive scores were: CYP1A1, ARNT2, HSP90AA1, ARNT, AIP, PTGES3, HSP90AB1, CYP1B1, ESR1, MAF, respectively. In addition, we showed that levels of AHR and its related genes were correlated with the immune infiltration and expression of immuno-regulators (immunoinhibitors, immunostimulators, MHC molecules) levels in cervical cancer. High expression of AHR, CYP1A1, HSP90AA1, and HSP90AB1 and low expression of ESR1 were negatively correlated with the prognoses of cervical cancer patients. The Cox multivariate regression showed that high expression of AHR ( HR = 1.874, 95% CI = 1.069–3.285, P = 0.028) and CYP1A1 ( HR = 1.822, 95%CI = 1.077–3.080, P = 0.025) were risk factors for prognosis in patients with cervical cancer. IHC results indicated that AHR and CYP1A1 were widely expressed in cervical cancer. These findings suggest that AHR and CYP1A1 may serve as prognostic biomarkers for determining prognosis and immune infiltration in cervical cancer.